Seltorexant is a Small Molecule owned by Johnson & Johnson, and is involved in 35 clinical trials, of which 27 were completed, 7 are ongoing, and 1 is planned.

Seltorexant (JNJ-7922, JNJ-42847922, MIN-202) is a selective orexin-2 receptor antagonist. Orexin maintain a long, consolidated waking period by activating waking monoaminergic and cholinergic neurons in the hypothalamus and brainstem regions. Orexin-2 receptor mediate both excitatory and inhibitory signals depending on the postsynaptic neurons. Orexins through orexin receptors are also involved in the regulation of the sleep-wake cycle. MIN-202 blocks orexin 2 receptor and reduces the neurotransmitters level that signal the brain to maintain vigilance and wakefulness.

The revenue for Seltorexant is expected to reach a total of $3.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Seltorexant NPV Report.

Seltorexant is originated and owned by Johnson & Johnson.

Seltorexant Overview

Seltorexant (JNJ-7922, JNJ-42847922, MIN-202) is under development for the treatment of major depressive disorder (MDD), Alzheimer’s disease (AD), and primary and secondary insomnia. It is administered orally as a capsule, film coated tablet and intravenous route. The drug candidate acts by targeting orexin-2 receptor. It is a new molecular entity (NME).

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Seltorexant

Report Segments
  • Innovator
Drug Name
  • Seltorexant
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.